Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
One example is below.
Q: "Although the story didn't cite the cost of appendectomy emergency or urgent surgery and we wish it had, we nonetheless will give it a satisfactory score because it at least cited what the editorial writer wrote, ""A secondary benefit is the savings to the hospital generated by minimizing staff and anesthesiologist presence late in the evening and during the wee hours of the morning."" As with our harms score above, although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Although the story didn't give absolute numbers, in this case we think it was sufficient for it to report that ""The scientists found no significant difference among the groups in the patients' condition 30 days after surgery or in the length of their operation or hospital stay."" Despite running less than 300 words, this story did an adequate job in explaining the quality of the evidence, including pointing out limitations. No disease-mongering here. The story meets the bare minimum requirement for this criterion in that it at least cited what an editorial stated. The focus of the story was on a study comparing emergency appendectomy with surgery done up to 12 hours later or beyond. This is the whole focus of the story and one we applaud when it begins: ""Appendectomy is the most common emergency surgery in the world, but it doesn't have to be."" There were no claims made about the novelty of this research, and we may have wished for a bit more context on this. Nonetheless, the potential for guiding future care decisions was made clear. Not applicable. Given that the story only pulled excerpts from the journal article and the accompanying editorial, and didn't include any fresh quotes from interviews, we can't be sure of the extent to which it may have been influenced by a news release."
A: Some appendicitis cases may not require 'emergency' surgery
Rationale: The paragraph mentions that "Appendectomy is the most common emergency surgery in the world, but it doesn't have to be." which is considered evidence for the output. Thus, the output is a valid claim.
Q: The news is a boost for the Spanish biotech company, which already sells Yondelis as a treatment for soft tissue sarcoma, a rare disease, and now hopes to address a much bigger commercial opportunity. Bradley Monk, an oncologist from the University of California Irvine Medical Center who led a Phase III trial of the drug, said Yondelis could be added to a short list of active drug therapies for recurrent ovarian cancer. "These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," Monk said in a statement. "This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much-needed option." Zeltia's drug, which it is developing with Johnson & Johnson, is unusual in that it is a synthetic version of a compound isolated from a type of sea squirt, a tubular marine animal. It works by binding to the DNA of cancer cells and blocking their ability to multiply. At 1445 GMT, Zeltia shares were down 5.4 percent at 5.43 euros, regaining ground after a low of 4.99 euros, while Spain's IBEX-35 blue chip index dropped 4.1 percent. "The stock's had a good run. This news is already in the price," a Madrid-based trader said. The Spanish company had already announced that Yondelis, its first product to reach the market, had shown positive results in the pivotal trial. But the actual results of the study, involving 672 women whose ovarian cancer had progressed after first-line treatment, were only disclosed at the annual meeting of the European Society of Medical Oncology (ESMO) in Stockholm. Monk said the results showed those women given a combination of Yondelis and Johnson & Johnson's chemotherapy drug Doxil had no progression of their cancer for an average of 7.3 months, against 5.8 months for women treated only with Doxil. In the case of women who had relapsed more than six months after getting first-line therapy, the median progression-free time was 9.2 months with Yondelis versus 7.5 months. In common with other anti-cancer agents, this suggests Yondelis is most active in patients who have gone a long time since receiving initial chemotherapy treatment. Zeltia plans to submit Yondelis for approval in Europe in the fourth quarter of this year. Johnson & Johnson is expected to file in the United States by the end of the year as well. The Spanish group has previously estimated that peak sales of Yondelis for ovarian cancer could be around 300 million euros ($420 million) in the European Union alone. Sales of the drug as a treatment for soft tissue sarcoma are forecast to be about 30 million euros this year. Yondelis, whose generic name is trabectedin, is currently approved for soft tissue sarcoma in Europe but not the U.S. The product is also being studied in smaller, Phase II trials for prostate, breast and childhood cancers.
A:
Zeltia drug delays progression of ovarian cancer.